Leukocytosis and thrombocytopenia occur during cardiopulmonary bypass (CPB) with extracorporeal circulation (ECC). Elevated circulating concentrations of macrophage colony-stimulating factor (M-CSF) are reported during thrombocytopenia and leukopenia of different origins. We have assessed M-CSF concentrations in 40 patients undergoing CPB with ECC. Plasma M-CSF concentrations were stable during ECC and increased at the 6th (7.3 ± 0.7 IU/µg protein) and 24th (8.6 ± 0.8 IU/µg protein) postoperative hour compared with pre-ECC values (4.9 ± 0.5 IU/µg protein). A deep thrombocytopenia was found during ECC and until the 24th postoperative hour. A drop of leukocyte counts was found during ECC followed by an increase after ECC weaning. While no correlation was found between M-CSF concentrations and the leukocyte counts, M-CSF values were positively correlated with platelet counts only before and during ECC. Thus, M-CSF is not implicated in the thrombocytopenia and the leukopenia generated during CPB with ECC. However, the elevated levels of M-CSF a few hours after the end of ECC might play a role in the inflammatory process often observed after CPB.

**Key words:** Cardiopulmonary bypass, CEC, Inflammation, M-CSF

### Plasma macrophage colony-stimulating factor levels during cardiopulmonary bypass with extracorporeal circulation

Y. Denizot, P. Fixe, E. Cornu and N. Nathan

Departments of 1Anaesthesia and Cardiovascular Surgery, CHRU Dupuytren, 2 Avenue Martin Luther King, 87042 Limoges, France

CA Corresponding Author
Fax: (+33) 05 55 05 67 92

### Introduction

Cardiopulmonary bypass (CPB) with extracorporeal circulation (ECC) results in major haematological changes including leukocytosis and thrombocytopenia. The release of several inflammatory compounds including cytokines, eicosanoids, platelet-activating factor (PAF), and activation of the coagulation and the complement cascade are suspected to play a role in these haematological disorders and in the pathogenesis of the inflammatory syndrome observed after CPB.

Monocyte/macrophage activation accompanies CPB. Macrophage colony-stimulating factor (M-CSF), also known as CSF-1, is a major regulator of the production as well as functional state of cells of the mononuclear-phagocytic lineage. M-CSF is produced by numerous cell types such as endothelial cells, monocytes/macrophages, T- and B-cells spontaneously or after induction. M-CSF acts on mature monocytes/macrophages, stimulating production of tumour necrosis factor (TNF), interferon, interleukin-6 (IL6), prostaglandins and CSFs. Some reports have highlighted the role of M-CSF in the pathogenesis of thrombocytopenia and leukopenia of various origins.

The purpose of this study was to assess plasma M-CSF concentrations during and after cardiac surgery with ECC. We also investigated the relationship between platelet and leukocyte counts and M-CSF levels during and after CPB.

### Patients and Methods

After ethical committee approval, 40 patients scheduled to undergo coronary artery bypass graft were included in this prospective study. All the patients gave written informed consent.

### Anaesthesia

All patients had a preoperative ejection fraction above 40%. Upon arrival on operating room, all patients received their usual oral cardiac medication, flunitrazepam (2 mg) and morphine (10 mg) intramuscularly. Anaesthesia was induced and maintained with titrated doses of fentanyl and flunitrazepam. Muscular relaxation was achieved with pancuronium (0.1 mg/kg). Bubble or membrane oxygenators were used according to the planned number of graft and surgical difficulties. The blood was harvested...
from surgical field and from the cell saver at the end of ECC and reinfused to all patients. All patients (except two with uneventful surgery) received high doses aprotinin. All the patients were managed by the same surgical anaesthetic team.

**Blood sampling and haematologic measurements**

Blood samples were collected from the radial artery catheter at the following times: before vascular cannulation and after opening the chest (T₀), during ECC just before (T₁) and after cross-clamp release (T₂), after weaning from ECC (T₃), at the 6th (T₄) and 24th postoperative hour (T₅) (Fig. 1). Two ml of blood were placed in EDTA then centrifuged to obtain plasma which was stored at −80°C until assay. Plasma samples were also collected from 36 healthy individuals to assess plasma M-CSF concentrations in controls. Platelet and leucocyte counts were determined in the radial artery blood at T₀, T₁, T₃, T₄ and T₅.

Haematological complications were biologically determined at T₀, T₁, T₃, T₄ and T₅ as follows: APTT values above 1.5, fibrinogen levels <1 g/l, factor V levels <30%, and platelet count <70,000 elements/mm³. Clinical bleeding was considered when blood loss reached values above 100 ml/h. Haematological complications were graded from 0 (absence) to 3 (biological trouble and significant bleeding leading to reoperation). Grade 1 haematological complications were assumed when biological abnormalities were present without clinical bleeding.

**M-CSF assay**

M-CSF production was determined by a self-made sandwich EIA procedure previously described. Briefly, polyclonal anti-human M-CSF immunoglobulins were coated on 96-well microtitre plates. Standard dilutions of M-CSF (400 to 6 international units per ml (IU/ml) of human M-CSF, international standard, NIBSC, Potters Bar, UK) and samples were transferred into wells and incubated overnight at 4°C. Plates were washed and anti-M-CSF-biotin conjugate was added to all wells and incubated overnight at 4°C. Plates were washed and avidine phosphatase (1 µg/ml) was added to wells and incubated for 1 h at 37°C. The revelation was performed with para-nitrophenyl-phosphate disodium (4 g/ml) for 15 min at 37°C. The reaction was blocked by addition of 50 µl of NaOH 10N to the wells. Colour development was measured at OD 405 nm. M-CSF levels in samples were calculated with respect to the calibration curve obtained with standard M-CSF. The sensitivity of the assay enables detection of plasma M-CSF levels as low as 10 IU/ml. Plasma M-CSF concentrations were expressed either as IU/ml for controls and for patients before surgery or as IU per microgram of protein content (IU/µg) to exclude the influence of haemodilution for operated patients. The proteinmia was determined at each time of blood sampling by the BCA Protein Assay Reagent (Pierce, Rockford, IL).

**Statistical analysis**

Results are expressed as mean ± SEM. Statistical analysis was performed by Kruskal Wallis analysis and Mann–Whitney U-test. A p < 0.05 was considered significant. Statistical analysis was performed using the statistics package ‘statgraphic’. Correlations between M-CSF levels and platelet or leucocyte counts were calculated by linear regression analysis.

**Results**

The demographic data of patients are shown in Table 1. Plasma M-CSF concentrations of coronary patients before ECC (223.7 ± 20.6 IU/ml, n = 40) were not statistically (p > 0.05, Mann–Whitney U-test) different compared with healthy individuals (198.3 ± 17.4 IU/ml, n = 36).

A significant (p < 0.01) drop in platelet and leucocyte counts was observed in the radial blood during ECC (Fig. 2). Platelet counts remained low at the 6th and 24th postoperative hour. By contrast leucocyte counts increased significantly (p < 0.01) after weaning of ECC and at the 6th and 24th postoperative hour. As shown in Fig. 2, plasma M-CSF concentrations were stable during ECC. Elevated levels (p < 0.01, Mann–Whitney U-test) of plasma M-CSF
Table 1. Demographic data (mean ± SEM)

<table>
<thead>
<tr>
<th></th>
<th>Patients (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>67 ± 1</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74 ± 2</td>
</tr>
<tr>
<td>Body surface area (m²)</td>
<td>1.84 ± 0.03</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>58.6 ± 2.7 (n = 33)</td>
</tr>
<tr>
<td>Preoperative left ventricle diastolic pressure (mmHg)</td>
<td>16.1 ± 1.6 (n = 36)</td>
</tr>
<tr>
<td>Number of grafts</td>
<td>3.0 ± 0.1</td>
</tr>
<tr>
<td>ECC duration</td>
<td>104 ± 6</td>
</tr>
<tr>
<td>Heparin doses (mg)</td>
<td>357 ± 11</td>
</tr>
<tr>
<td>Protamine doses (mg)</td>
<td>267 ± 9</td>
</tr>
<tr>
<td>Peroperative blood loss (ml)</td>
<td>603 ± 47</td>
</tr>
</tbody>
</table>

Table 2. Correlations between plasma M-CSF levels and platelet and leukocyte counts during and after CPB. (n): number of patients

<table>
<thead>
<tr>
<th>Time of blood sampling</th>
<th>Platelets</th>
<th>Leukocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>T₀ (n = 32)</td>
<td>r = 0.39</td>
<td>r = 0.21</td>
</tr>
<tr>
<td></td>
<td>p = 0.020</td>
<td>p = 0.22</td>
</tr>
<tr>
<td>T₁ (n = 32)</td>
<td>r = 0.39</td>
<td>r = 0.24</td>
</tr>
<tr>
<td></td>
<td>p = 0.022</td>
<td>p = 0.17</td>
</tr>
<tr>
<td>T₃ (n = 31)</td>
<td>r = 0.29</td>
<td>r = -0.15</td>
</tr>
<tr>
<td></td>
<td>p = 0.099</td>
<td>p = -0.12</td>
</tr>
<tr>
<td>T₄ (n = 33)</td>
<td>r = 0.02</td>
<td>r = 0.41</td>
</tr>
<tr>
<td></td>
<td>p = 0.88</td>
<td>p = 0.46</td>
</tr>
<tr>
<td>T₅ (n = 33)</td>
<td>r = -0.04</td>
<td>p = 0.78</td>
</tr>
</tbody>
</table>

Discussion

This study shows that plasma M-CSF concentrations are stable during ECC and increase at the 6th and 24th postoperative hour compared with pre-ECC values. While lipidic mediators are produced chiefly during ECC, elevated cytokine concentrations are often found after few hours. The time-course of M-CSF concentrations during cardiac surgery fits well with those of the other cytokines so far assessed. We may speculate that the monocytes, lymphocytes, and polymorphonuclear neutrophils ‘primed’ by CPB might be implicated in these elevated M-CSF concentrations. However a lowering M-CSF degradation might also explain our results. M-CSF receptors is almost totally cleared from the
circulation by specific M-CSF receptors on hepatic and splenic macrophages.\(^{1,12}\) A down-regulation of M-CSF receptors at the surface of macrophages has been reported in response to inflammatory mediators and cytokines.\(^9\) Such a phenomenon might also explain the elevated M-CSF levels after CPB. The production of M-CSF by peripheral blood leukocytes of patients undergoing CPB with ECC deserves now to be assessed.

M-CSF is suspected to play a role in the fall of platelet counts during pregnancy,\(^{14}\) and in patients with immune thrombocytopenic purpura.\(^{15}\) In this study M-CSF levels are stable during ECC. While M-CSF levels are positively correlated with platelet counts at the beginning of ECC, no correlation is found with leukocyte counts. Thus, M-CSF is not implicated in the thrombocytopenia and the leukopenia which occur at the beginning of ECC. Various mediators released during coronary reflow amplify vascular cell margination and may participate to vascular obstruction and to the no-reflow phenomenon.\(^7\)

Immediately after ECC, plasma M-CSF concentrations are similar to pre-ECC values denying the involvement of M-CSF in the haematologic changes generated during the coronary reflow. After ECC, the increase of leukocyte counts occurs before the increase of M-CSF concentration denying its role in the post-ECC leukocytosis. In addition no difference could be documented between M-CSF concentrations after ECC according to the grade of haematological complications.

The concept that there is a marked synergy between the effects of the various mediators released during cardiac surgery is now widely accepted.\(^2\) A combination of small amounts of them may be more active than a large release of one by itself. M-CSF might play a role in the inflammatory process observed after cardiac surgery since the key cells of the inflammatory response to CPB (i.e. monocytes, polymorphonuclear neutrophils and lymphocytes) produce M-CSF in response to cytokines and produce cytokines in response to M-CSF.\(^8\)–\(^13\) In addition elevated circulating amounts of granulocyte-CSF (G-CSF) have been recently found after cardiac surgery,\(^20\) strengthening that the involvement of growth factors after CPB deserves further evaluations.

References


Acknowledgements. PE is the recipient of a grant from the 'Ligue Nationale Contre le Cancer' (Comité de la Haute Vienne).

Received 1 August 1996;
accepted 28 August 1996

Mediators of Inflammation Vol 5 1996 361
Submit your manuscripts at http://www.hindawi.com